SEARCH BY
| Category | Company |
|---|---|
| Founded | 2002 |
| Sector | Life Science |
| Employees | 2,391 |
| Revenue | 3.56T KRW (2024) |
Celltrion is a biopharmaceutical company specializing in the development of “biosimilars” for monoclonal antibody drugs. Celltrion provides biosimilars for auto-immune diseases and various cancers; generic pharmaceuticals; and covid-19 test kits. Celltrion was founded in 2002 and is based in Incheon, South Korea.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Add-on Acquisition M&A Deals | 1 of 1 |
| Country: Switzerland M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-11-30 |
Takeda Pharmaceutical Co. - Primary Care Product Assets
Osaka, Japan Takeda Pharmaceutical Co. Ltd. - Primary Care 18 products include prescription medicines such as Nesina (diabetes), Actos (diabetes), and Edarbi (hypertension) which were developed for the global market, as well as OTC (Over-the-counter) products well known to consumers such as Whituben (cold remedy). Nesina and Edarbi. |
Buy | $278M |
